Showing 421-440 of 746 for: Cochrane Systematic Reviews > Pharmacotherapeutics 
- Lamotrigine for chronic neuropathic pain and fibromyalgia in adults
Cochrane Systematic Reviews, 28-May-2019
This is an update of the original Cochrane review entitled Lamotrigine for acute and chronic pain published in Issue 2, 2007, and updated in Issue 2, 2011. Some antiepileptic medicines have a place in the treatment of neuropathic pain (pain due to nerve d
- Lamotrigine for schizophrenia
Cochrane Systematic Reviews, 26-Apr-2008
Treating the 20-30% of people with schizophrenia whose symptoms are resistant to treatment can be problematic. Adding lamotrigine to ongoing antipsychotic treatment has shown to be of benefit in preliminary studies.
- Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
Cochrane Systematic Reviews, 11-Nov-2021
Many infants born preterm develop bronchopulmonary dysplasia (BPD), with lung inflammation playing a role. Corticosteroids have powerful anti-inflammatory effects and have been used to treat individuals with established BPD. However, it is unclear whether
- Laxatives for the management of constipation in people receiving palliative care
Cochrane Systematic Reviews, 13-May-2015
This article describes the second update of a Cochrane review on the effectiveness of laxatives for the management of constipation in people receiving palliative care. Previous versions were published in 2006 and 2010 where we also evaluated trials of met
- Laxatives for the treatment of hemorrhoids.
Cochrane Systematic Reviews, 4-Aug-2008
Symptomatic hemorrhoids are a common medical condition, which increase in prevalence in women during pregnancy and postpartum. Although the evidence appears to be inconclusive, narrative reviews and clinical practice guidelines recommend the use of laxati
- Leukotriene receptor antagonist for prolonged non-specific cough in children
Cochrane Systematic Reviews, 14-Nov-2010
Non-specific cough is defined as non-productive cough in the absence of identifiable respiratory disease or known aetiology. It is commonly seen in paediatric practice. These children are treated with a variety of therapies including a variety of asthma m
- Leukotriene receptor antagonists for non‐cystic fibrosis bronchiectasis
Cochrane Systematic Reviews, 24-Apr-2000
Leukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis.
- Lithium for schizophrenia
Cochrane Systematic Reviews, 28-Oct-2015
Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary anti-psychotic drug treatment. In these cases, various add-on medications are used, among them lithium.
- Lithium versus antidepressants in the long‐term treatment of unipolar affective disorder
Cochrane Systematic Reviews, 18-Oct-2006
The main rationale for the use of lithium in the long-term treatment of unipolar affective disorder is its efficacy in treating bipolar affective disorder and resistant depression. However, there is considerable uncertainty about which pharmacological int
- Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children
Cochrane Systematic Reviews, 29-Mar-2009
The addition of a long acting beta agonist (LABA) to inhaled corticosteroid (ICS) therapy can improve asthma symptoms and reduce exacerbations. The addition of LABA may also have an ICS-sparing effect and permit a reduction in ICS maintenance dose.
- Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid
Cochrane Systematic Reviews, 22-Jul-2014
Asthma is a common respiratory disease among both adults and children and short acting inhaled beta-2 agonists are used widely for 'reliever' bronchodilator therapy. Long acting beta-2 agonists (LABA) were introduced as prospective 'symptom controllers' i
- Long‐acting beta2‐agonists for poorly reversible chronic obstructive pulmonary disease
Cochrane Systematic Reviews, 19-Jul-2006
Chronic obstructive pulmonary disease (COPD) is characterised by partially reversible airflow limitation. Many patients have little reversibility to short acting bronchodilators, but long acting bronchodilators are frequently advocated.
- Long‐acting beta2‐agonists versus theophylline for maintenance treatment of asthma
Cochrane Systematic Reviews, 18-Jul-2007
Theophylline and long acting beta-2 agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma. They represent different classes of drug with differing side-effect profiles.
- Long‐term antibiotics for preventing recurrent urinary tract infection in children
Cochrane Systematic Reviews, 1-Apr-2019
Urinary tract infection (UTI) is common in children. Symptoms include fever, lethargy, anorexia, and vomiting. UTI is caused by Escherichia coli in over 80% of cases and treatment is a course of antibiotics. Due to acute illness caused by UTI and the risk
- Long‐term effects of weight‐reducing drugs in people with hypertension
Cochrane Systematic Reviews, 17-Jan-2021
This is the third update of this review, first published in July 2009. All major guidelines on treatment of hypertension recommend weight loss; anti-obesity drugs may be able to help in this respect.
- Long‐term opioid management for chronic noncancer pain
Cochrane Systematic Reviews, 20-Jan-2010
Opioid therapy for chronic noncancer pain (CNCP) is controversial due to concerns regarding long-term effectiveness and safety, particularly the risk of tolerance, dependence, or abuse.
- Low dosage tricyclic antidepressants for depression
Cochrane Systematic Reviews, 21-Jul-2003
Tricyclic antidepressants are still extensively prescribed worldwide. Evidence for the recommended dosage of tricyclics, however, is poor.
- Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes
Cochrane Systematic Reviews, 2-Aug-2010
Acute coronary syndromes (ACS) are an important source of morbidity and mortality. Despite weak evidence for the use of unfractionated heparin (UFH) for acute coronary syndromes it is considered an accepted treatment for unstable angina and non-ST segment
- Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke
Cochrane Systematic Reviews, 4-Apr-2017
Low-molecular-weight heparins (LMWHs) and heparinoids are anticoagulants that may have more powerful antithrombotic effects than standard unfractionated heparin (UFH) but a lower risk of bleeding complications. This is an update of the original Cochrane R
- Loxapine for schizophrenia
Cochrane Systematic Reviews, 17-Oct-2007
Some authors have suggested that loxapine is more effective than typical antipsychotics in reducing the negative symptoms of schizophrenia, that extrapyramidal adverse effects are not usually seen at clinically effective antipsychotic doses and that it sh
